My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CASI Pharmaceuticals, Inc. - Ordinary Shares (NQ:CASI)

1.860 -0.050 (-2.62%)
Streaming Delayed Price Updated: 10:50 AM EDT, Sep 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about CASI Pharmaceuticals, Inc. - Ordinary Shares

< Previous 1 2 3 4 5 6 Next >
CASI Pharmaceuticals Announces Safety Monitoring Committee Recommendation to Escalate CID-103 Dose to Next Cohort in Phase 1 Immune Thrombocytopenia (ITP) Study
Via ACCESS Newswire
CASI Pharmaceuticals to Present at H.C. Wainwright 27th Annual Global Investment Conference
Via ACCESS Newswire
CASI Pharmaceuticals Appoints Barbara Krebs-Pohl, PhD to Board of Directors
Via ACCESS Newswire
12 Health Care Stocks Moving In Friday's After-Market Session
 
Via Benzinga
CASI Pharmaceuticals Announces Second Quarter 2025 Business and Financial Results
Via ACCESS Newswire
CASI Pharmaceuticals to Participate at Cantor Global Healthcare Conference 2025
Via ACCESS Newswire
These stocks are moving in today's pre-market session
Before the US market kicks off on Monday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers. 
Via Chartmill
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
Why Dayforce Shares Are Trading Higher By Around 21%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
 
Via Benzinga
Wondering what's happening in today's after-hours session?
As the regular session of the US market on Friday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment. 
Via Chartmill
Top movers in Friday's session
Curious about what's happening in today's session? Check out the latest stock movements and price changes. 
Via Chartmill
What's going on in today's session
Here are the top movers in Monday's session, showcasing the stocks with significant price changes. 
Via Chartmill
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
Loop Industries (NASDAQ: LOOP) Ignites Paradigm Shift – Twist™ A Breakthrough in Circular Sustainability – More Stocks Inside
Via AB Newswire
Topics Economy
Top stock movements in today's session.
Stay up-to-date with the latest market trends in the middle of the day on Monday. Explore the top gainers and losers during today's session in our detailed report. 
Via Chartmill
CASI Pharmaceuticals Announces FDA Clearance of IND Application for CID-103 in Renal Allograft Antibody-Mediated Rejection (AMR)
Via ACCESS Newswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
 
Via Benzinga
CASI Pharmaceuticals Appoints David Cory as Chief Executive Officer to Lead U.S. Company Focused on Clinical Development of CID-103, a Potential Best in Class Anti-CD38 Program
Via ACCESS Newswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
The trading volume of these stocks is deviating from the norm in today's session.
These stocks have an unusual volume in today's session 
Via Chartmill
CASI Pharmaceuticals Provides Business and Clinical Update
Via ACCESS Newswire
CASI Pharmaceuticals Announces First Quarter 2025 Business and Financial Results
Via ACCESS Newswire
CASI Pharmaceuticals Enters Into Definitive Agreement for the Divestiture of Assets in China
Via ACCESS Newswire
CASI Pharmaceuticals Receives Nasdaq Deficiency Notice Regarding Minimum Market Value Requirement
Via ACCESS Newswire
CASI Pharma Stock Rises On $20M Buyout Offer From CEO For China Business Operations: Retail Remains Extremely Bullish
The company said that its special committee of the board of directors will evaluate the proposed transaction. 
Via Stocktwits
CASI Pharmaceuticals Announces Receipt of An Updated Non-Binding Proposal to Acquire Entire China Business of the Company
Via ACCESS Newswire
CASI Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Business and Financial Results
Via ACCESS Newswire
CASI Announces First Patient Dosed in Phase 1/2 Clinical Trial of CID-103 in Immune Thrombocytopenia
Via ACCESSWIRE
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.